{"id":"W4366339435","doi":"10.1200/jco.22.01792","title":"Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":211,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Cilag; Foundation Medicine; Genentech; Eisai; Astellas Pharma; Eli Lilly and Company; Ono Pharmaceutical; G1 Therapeutics; GlaxoSmithKline; UroGen Pharma; Bavarian Nordic; Silverback Therapeutics; Ipsen; Mirati Therapeutics; Clovis Oncology; Janssen Biotech; Les Laboratories Pierre Fabre; Pfizer; Incyte; Merck KGaA; Taiho Pharmaceutical; Regeneron Pharmaceuticals; Gilead Sciences; Exelixis; Sanofi; Amgen; EUSA Pharma; AstraZeneca; Bristol-Myers Squibb","keywords":"Avelumab; Medicine; Clinical endpoint; Metastatic Urothelial Carcinoma; Hazard ratio; Internal medicine; Bladder cancer; Clinical trial; Progression-free survival; Oncology; Urothelial carcinoma; Chemotherapy; Cancer; Immunotherapy; Confidence interval; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005194217,0.0004011176,0.00144756,0.0003141048,0.0003447456,0.001110249,0.0003865604,0.0005914549,0.001688662],"category_scores_gemma":[0.003544797,0.0002510187,0.001760706,0.0006499072,0.0003672825,0.001142747,0.0003031945,0.002056337,0.0004064752],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006076553,"about_ca_system_score_gemma":0.0005970752,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000442307,"about_ca_topic_score_gemma":0.001482406,"domain_scores_codex":[0.99864,0.0006676333,0.0001497261,0.0002013652,0.0002074404,0.0001337475],"domain_scores_gemma":[0.9975461,0.0007522805,0.0007069192,0.0003457105,0.0001805268,0.0004683338],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5772989,0.007750978,0.05536675,0.003120051,0.009091237,0.0002596719,0.0003228277,0.004480795,0.01809241,0.0004742777,0.0131894,0.3105526],"study_design_scores_gemma":[0.2284685,0.3605346,0.3395581,0.001000905,0.01359698,0.00163458,0.0002451551,0.005062881,0.01158015,0.001580328,0.03652958,0.0002081584],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9627044,0.02600689,0.001110988,0.0008150445,0.0002010643,0.0006551347,0.004649738,0.00009168359,0.00376499],"genre_scores_gemma":[0.9771922,0.007312824,0.001276841,0.0009611374,0.0001851584,0.0007144798,0.01057978,0.00003601192,0.001741515],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005194217,"threshold_uncertainty_score":0.02746999,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1206717529403053,"score_gpt":0.4287012932690438,"score_spread":0.3080295403287385,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}